Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial

This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.

Inclusion Criteria:

• Adult, Age>44 years, competent to provide consent
• Confirmed COVID-19, via a positive nucleic acid assay for COVID-19 within the last 7 days

Exclusion Criteria:

• Participants already prescribed chloroquine, hydroxychloroquine, or azithromycin
• Allergy to hydroxychloroquine or azithromycin
• History of bone marrow transplant
• Known G6PD (Glucose-6-Phosphate Dehydrogenase Deficiency) deficiency
• Chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or Glomerular Filtration Rate < 20ml/min/1.73m2
• Liver disease (e.g. Child Pugh score ≥ B or AST (Aspartate Transaminase)>2 times upper limit)
• Psoriasis
• Porphyria
• Known cardiac conduction delay (QTc > 500mSec) or taking any prescription medications known to prolong QT interval
• Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone
• Prisoner
• Weight < 35kg
• Inability to follow-up - no cell phone or no address or not Spanish or English speaking
• Receipt of any experimental treatment for SARS-CoV-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation
• No symptoms attributable to COVID-19
• Pregnant or nursing